胶原蛋白IV

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill. HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth. Scalp Aging & Hair Loss Continue Reading HAIRNA Exosome Hair Fill 2XSOME Alopecia and other hair anomalies can happen due to an array of causes, the most common being: 1. Loss of collagen in hair follicles due to aging 2. Loss of capillaries in the scalp, cutting oxygen and nutrient supply to the follicles 3. Decrease in follicle size and increased oil production due to DHT hormone expression 4. Reduced scalp regeneration and healing capacity due to compromised skin barrier 5. Reduced pigment transport due to loss of melanocytes (grey hair) Additional Active Ingredient 01 Biotinoyl Tripeptide-1 Biotin Tripeptide-1 is a three amino acid peptide that combines the famous collagen fragment, GHK with Biotin, a well-known supplement for stronger hair and nails. Biotinoyl Tripeptide-1 Benefits 1. Hair Cell Activation Promotes keratinocyte proliferation at the follicle base and helps optimal hair anchorage by stimulating the synthesis of adhesion molecules - Laminin 5 and Collagen IV. 2. Gene Expression Stimulation Stimulates the expression of the Ki-67 gene, a proliferation marker protein associated with cellular proliferation as well as tissue recovery. 3. Hair Cell Metabolism Regulation Promotes scalp microcirculation and stimulates cell communication, improving oxygen and nutrient supply to the hair follicles. 02 Copper Tripeptide-1 Copper Tripeptide-1 (GHK-Cu) is a copper-peptide complex found naturally in bodily fluids such as plasma and saliva. With copper depletion being one of the causes for signs of skin aging and hair thinning, this tripeptide is quickly becoming a popular ingredient for hair and scalp treatments. Copper Tripeptide-1 Benefits 1. Hair Follicle Enlargement While studying GHK-Cu's wound healing properties, an enlargement of hair follicles around the area was found which eventually led to the discovery that copper peptides stimulate hair growth by stimulating follicular cell proliferation. 2. Hair Growth Cycle Regulation Copper peptides stimulate and prolong the hair growth phase (Anagen), resulting in more time for active hair regrowth and thicker hair strands. They are also involved in shortening the inactive phase of the hair follicles (Telogen). 3. DHT Hormone Inhibition Dihydrotestosterone (DHT), a hormone converted from testosterone, is the main cause of androgenetic hair loss. DHT is converted thanks to an enzyme known as 5-alpha reductase, which peptides have been shown to obstruct. 03 Polypeptide 1. sh-Polypeptide-1 (FGF2) Synthesized copy of the human gene coding for Basic Fibroblast Growth Factor (FGF2). Stimulates fibroblast and keratinocyte cell growth and proliferation, as well as the synthesis of collagen and other extracellular matrix components, promoting skin barrier health. 2. sh-Polypeptide-4 (SCF) Synthesized copy of the human gene coding for Stem Cell Factor (SCF). Plays an important role in the formation of blood cells and melanocytes, regulating the survival and proliferation of melanocytes in adults to maintain a normal pigment transport (grey hair prevention). 3. sh-Polypeptide-12 (NOG) Synthesized copy of the human gene coding for Noggin protein (NOG). Noggin is a signaling molecule that plays a role in tissue development and the derivation of specialized cells.Studies show that Noggin signaling is required for induction of the hair follicle growth phase (Anagen). HAIRNA Exosome Hair Fill & The Hair Growth Cycle Biotin Tripeptide-1 is a three amino acid peptide that combines the famous collagen fragment, GHK with Biotin, a well-known supplement for stronger hair and nails. The resulting Biotinoyl Tripeptide-1 has shown hair regrowth effects comparable to those of Minoxidil. In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck. Backed by extensive clinical research, Maypharm products have been thoroughly tested and embraced by countless individuals to worldwide acclaim. Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat. For further details, please contact us at [email protected], or visit our website at SOURCE Maypharm

Patienttreated in trial achieved a remission after eight weeks of treatment, demonstrating a significant reduction in proteinuria ELX-02 well-tolerated in study, with no discontinuations to date WATERTOWN, Mass., May 24, 2023 (GLOBE NEWSWIRE) --Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the company intends to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations, following the achievement of remission in one patient in its Phase 2 clinical study. The patient demonstrated a significant reduction in urine protein creatinine ratio (UPCR) from baseline. Consistent with prior clinical studies, ELX-02 was well tolerated in this trial. “The achievement of a remission in one of the first two patients with Alport syndrome with nonsense mutations in this trial of ELX-02 is a very encouraging result, as patients with this rare disease rarely demonstrate a reduction in proteinuria,” said Detlef Bockenhauer, MD., Ph.D., Professor of Paediatric Nephrology at University College London and Honorary Consultant at Great Ormond Street Hospital NHS Foundation Trust, London. “Based on the efficacy and tolerability to date, additional clinical testing is warranted in this patient population in need of disease-modifying treatments.” Topline Results of ELX-02 Phase 2 Trial for Alport Syndrome Eloxx has dosed three patients with ELX-02 in the ongoing proof-of-concept Phase 2 open-label clinical trial (NCT05448755). Two patients have now completed dosing and the third patient is still receiving ELX-02. One patient that has completed dosing achieved a remission, defined as a UPCR decline greater than or equal to 50%. For this patient, five out of eight UPCR readings produced an average of 53% below baseline. Spontaneous reductions in proteinuria are not expected in this population, providing added weight to this result. The patient achieving remission also demonstrated a significant reduction (-49%) (-p-value p=0.009) in UPCR from baseline versus values collected over the treatment period. The UPCR value for week 6 was excluded from this analysis as it was deemed to be unreliable due to delayed processing over a holiday period, potentially resulting in protein degradation and inaccurate proteinuria readings. No significant change in UPCR was seen in the other patient that has completed 8 weeks of dosing. Both patients had the same Col4A4 mutation, but were being treated with substantially different levels of renin-angiotensin-aldosterone system (RAAS) inhibitors. Assessment of COL IV protein restoration remains ongoing as both patients had Col4A4 mutations and the kidney biopsy assay was designed to assess COL IVA5 protein expression. Consistent with previous clinical studies, ELX-02 has been generally well tolerated with no discontinuations to date. Kidney biopsies from both patients after 8 weeks of dosing demonstrated no evidence of nephrotoxicity, further demonstrating tolerability. “We are incredibly pleased with these initial findings from our Phase 2 trial of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. These patients have significant unmet medical needs, with no disease modifying treatments currently available,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. “Following completion of the third patient in the trial, we plan to discuss the findings with the FDA with the goal of advancing the program into a pivotal trial, pending obtaining the necessary capital.” Eloxx intends to provide more detailed results from the trial at an upcoming medical meeting. About the Phase 2 Clinical Study This Phase 2 trial includes Alport syndrome patients with Col4A5 and Col4A3/4 nonsense mutations in the COL4 gene. Patients will be dosed with ELX-02 for two months with a three month follow-up. In addition to the primary endpoint of safety, the key secondary efficacy endpoint of change from baseline in proteinuria will be measured every two weeks. Treatment effect on proteinuria is a well-validated surrogate endpoint for several renal indications and may be a good predictor of treatment outcomes. For eligible patients, expression of COL4 will also be measured at the end of the two month treatment period. About Alport syndrome Alport syndrome is a genetic disorder characterized by kidney disease with high levels of proteinuria, hearing loss and eye abnormalities caused by mutations in the genes (COL4A3, COL4A4, and COL4A5) needed for production of type 4 collagen. Approximately 6% to 7% of Alport syndrome patients, or approximately 9,400 to 12,750 individuals, are estimated to have nonsense mutations. These patients have significantly worse clinical outcomes than other Alport patients and have no disease modifying treatment options. About Eloxx Pharmaceuticals Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZMTM chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in Phase 2 clinical development for the treatment of Alport syndrome in patients with nonsense mutations. For more information, please visit . Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding our cash runway and our ability to comply with the covenants in our debt agreement, the expected timing of and results from trials of our product candidates and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; our ability to meet the continued listing requirements of the Nasdaq Capital Market; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC’s website at and the “Financials & Filings” page of our website at . All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Investors John Woolford john.woolford@westwicke.com 443.213.0506 Media Laureen Cassidy laureen@outcomescg.com SOURCE: Eloxx Pharmaceuticals, Inc.

Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in one patient to date Received U.S. Food and Drug Administration (FDA) clearance to begin a single ascending dose (SAD) clinical trial for ZKN-013 for the potential treatment of recessive Dystrophic Epidermolysis Bullosa (RDEB) with nonsense mutations WATERTOWN, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended March 31, 2023 and provided a business update. “We are approaching a significant milestone for Eloxx, with topline data, including kidney biopsy results, expected for ELX-02 in Alport syndrome in the coming weeks,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. “In addition, ZKN-013, our lead TURBO-ZM™ based molecule, is the first program developed from hit to lead and our excitement for the program continues to grow. Eloxx has additional promising TURBO-ZM based discovery programs in cystic fibrosis (fully funded by the Cystic Fibrosis Foundation) and in certain cMYC-overexpressing cancers.” First Quarter 2023 and Subsequent Highlights Alport Syndrome Alport syndrome is a rare genetic disorder characterized by kidney disease with high levels of proteinuria, hearing loss and eye abnormalities.Eloxx has dosed three patients with ELX-02 in the ongoing proof-of-concept Phase 2 open-label clinical trial (NCT05448755). Meaningful protein reduction has been observed in one patient to date. We will be evaluating expression of COL IV protein in these three patients at the end of dosing and measuring proteinuria every two weeks. Topline results are expected in the first half of 2023. Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Junctional Epidermolysis Bullosa (JEB) In May 2023, Eloxx announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application to initiate a single ascending dose (SAD) clinical trial in healthy volunteers for ZKN-013 for the potential treatment of RDEB with nonsense mutations. RDEB is a rare skin disease characterized by mutations in Collagen 7 gene.Further SAD and multiple ascending dose (MAD) testing is expected to be conducted following the completion of the planned dose cohorts in the SAD study and discussion with the FDA. The MAD testing could potentially include RDEB patients given the strong benefit/risk in patients cited by the FDA.Recent preclinical results demonstrated read-through activity of ZKN-013 in multiple COL7 genotypes across multiple RDEB patient derived fibroblasts and keratinocytes. In this trial, read-through activity resulted in up to an 18-fold increase in full-length COL VII protein levels. Prolonged treatment with ZKN-013 was shown to further increased COL VII protein levels. Functionality of the restored full-length COL VII protein was observed. These results have been accepted for presentation at an upcoming medical conference. Familial Adenomatous Polyposis (FAP) Eloxx also plans to develop ZKN-013 to treat FAP, targeting a subset of patients that have nonsense mutations in the Adenomatous Polyposis Coli (APC) gene that is truncated in these patients.In January 2023, Eloxx published positive results from a study in the APCMin (multiple intestinal neoplasia) model evaluating the potential of ZKN-013 to treat FAP. The APCMin mouse is a translationally validated model for drug development for FAP. In the APCMin model, treatment with ZKN-013 demonstrated a decrease in intestinal polyps and adenomas, resulting in increased survival. The publication also included in vitro and in vivo results demonstrating that ZKN-013 inhibited the growth of human colon carcinoma cells with APC nonsense mutations, and promoted read through of premature stop codons in the APC gene, leading to functional restoration of full-length APC protein. First Quarter 2023 Financial Results For the three months ended March 31, 2023, we incurred a net loss of $6.2 million, or $2.88 per share, which included $0.6 million in stock-based compensation. For the same period in the prior year, we incurred a net loss of $11.6 million, or $5.36 per share, which included $0.9 million in stock-based compensation. R&D expenses were $3.5 million for the three months ended March 31, 2023, which included $0.3 million in stock-based compensation. For the same period in the prior year, R&D expenses were $7.9 million, which included $0.4 million of stock-based compensation. The decrease was primarily related to a decrease in clinical trial expenses for activities related to inhaled delivery of ELX-02 in cystic fibrosis and a decrease in clinical trial expenses related to a decrease in Cystic Fibrosis Foundation funded activities. General and administrative (G&A) expenses were $2.0 million for the three months ended March 31, 2023, which included $0.3 million in stock-based compensation. For the same period in the prior year, G&A expenses were $3.1 million, which included $0.6 million of stock-based compensation. The decrease was primarily related to a decrease in salaries and other personal related costs, a decrease in expenses attributable to professional and consulting fees, and a decrease in facility and overhead expenses. As of March 31, 2023, we had unrestricted cash and cash equivalents of $4.9 million. In March 2023, we amended the terms of the Hercules Term Loan Agreement and repaid $7.5 million of the outstanding principal. The minimum qualified cash balance requirement was reduced to $2.25 million and the interest only payment period was extended to September 1, 2023, at which time the Company will be required to begin making principal payments. Assuming that we initiate Phase 3 clinical trial activities in the third quarter of 2023, our expectation is that our current cash position and assuming maintaining compliance with our debt covenants, will be sufficient to fund our operations into the third quarter of 2023. About Eloxx Pharmaceuticals Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in Phase 2 clinical development for the treatment of Alport syndrome in patients with nonsense mutations. For more information, please visit www.eloxxpharma.com. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding our cash runway and our ability to comply with the covenants in our debt agreement, the expected timing of and results from trials of our product candidates and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; our ability to meet the continued listing requirements of the Nasdaq Capital Market; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the “Financials & Filings” page of our website at https://investors.eloxxpharma.com/financials-filings. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact InvestorsJohn Woolfordjohn.woolford@westwicke.com443.213.0506 MediaLaureen Cassidylaureen@outcomescg.com ELOXX PHARMACEUTICALS, INC. AND SUBSIDIARIESUNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS(Amounts in thousands, except share and per share data) Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $3,488 $7,899 General and administrative 1,995 3,054 Total operating expenses 5,483 10,953 Loss from operations (5,483) (10,953)Other expense, net 747 667 Net loss $ (6,230) $ (11,620) Net loss per share, basic and diluted $ (2.88) $ (5.36)Weighted average number of shares of common stock used in computing net loss per share, basic and diluted 2,166,356 2,166,275 ELOXX PHARMACEUTICALS, INC. AND SUBSIDIARIESUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands, except share and per share data) March 31, 2023 December 31, 2022ASSETS Current assets: Cash and cash equivalents $4,904 $19,207 Restricted cash 261 261 Prepaid expenses and other current assets 1,238 661 Total current assets 6,403 20,129 Property and equipment, net 143 169 Operating lease right-of-use asset 654 825 Total assets $ 7,200 $ 21,123 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable $2,434 $3,020 Accrued expenses 2,230 2,799 Current portion of long-term debt 1,536 3,980 Advances from collaboration partners 12,535 12,535 Current portion of operating lease liability 667 712 Derivative liabilities 58 45 Total current liabilities 19,460 23,091 Long-term debt, net of current portion 4,027 8,557 Operating lease liability 6 135 Total liabilities 23,493 31,783 Total stockholders’ deficit: (16,293) (10,660)Total liabilities and stockholders’ deficit $ 7,200 $ 21,123 SOURCE: Eloxx Pharmaceuticals, Inc.